Actively Recruiting

Phase 4
Age: 65Years +
All Genders
ID06486792

Stroke Prevention in Ischemic Stroke With Covert Atrial Fibrillation Using Anticoagulants or Aspirin

Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-06-05

1148

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying patients aged 65 and older who have recently experienced an ischemic stroke with no known cause. These patients might have undetected atrial fibrillation (AF) that was not found during their initial hospital stay. The study aims to evaluate the benefits and risks of using anticoagulant treatment compared to aspirin during the period after hospital discharge when AF detection is ongoing. This research addresses the uncertainty around the best treatment strategy to prevent recurrent strokes in this group. Participants will be randomly assigned to receive either anticoagulant therapy (such as vitamin K antagonists targeting an INR of 2-3 or newer anticoagulants like apixaban, rivaroxaban, or dabigatran) or aspirin at doses from 75 to 300 mg per day. They will be monitored for atrial fibrillation using devices like Holter ECGs, wearable monitors, or implantable loop recorders for up to 12 months. If AF is detected, anticoagulant treatment continues; if not, patients may switch to aspirin after 6 to 12 months. During the study, participants will be regularly evaluated for the occurrence of fatal or nonfatal ischemic strokes or peripheral emboli, with follow-up lasting 12 months. Researchers will assess how well AF detection tools identify true AF cases over three weeks and monitor other stroke-related outcomes. Safety and treatment adherence will be tracked throughout the follow-up period to better understand the impact of these treatment strategies on stroke prevention.

CONDITIONS

Brief Title

Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation

Who Can Participate

Age: 65Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged 65 years or older
  • Recent cerebral infarction (less than 15 days) confirmed by MRI or head CT
  • No known atrial fibrillation before stroke and none detected during hospital stay
  • Suspected atrial fibrillation based on specific clinical or imaging patterns
  • Plan to monitor atrial fibrillation using Holter ECG, wearable device, or implantable loop recorder
  • Rankin score of 4 or less
  • Signed informed consent
  • Affiliated to social security
Not Eligible

You will not qualify if you...

  • Known cause of stroke identified by ASCOD classification
  • Symptomatic brain hemorrhage (microbleeds alone do not exclude)
  • Uncontrolled hypertension as judged by investigator
  • Clear indication for anticoagulant or antiplatelet therapy
  • Contraindications to anticoagulant or antiplatelet therapy
  • Intercurrent disease interfering with study evaluation or follow-up
  • Participation in another interventional clinical trial
  • Use of contraception in women of childbearing potential
  • Patients under guardianship or curatorship

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to 12 months

Participants receive either anticoagulant treatment or aspirin according to their randomization arm to prevent recurrent stroke during the search period for atrial fibrillation.

Regular visits during treatment period (frequency per protocol)

Follow-up

Duration - Up to 12 months post-treatment start

Participants are monitored for the occurrence of ischemic stroke, peripheral emboli, and detection of atrial fibrillation after treatment.

Follow-up visits as scheduled during the 12 month period

Trial Site Locations

Total: 1 location

1

Bichat Hospital

Paris, Paris, France, 75018

Actively Recruiting

Loading map...

Research Team

P

Philippa Lavallée, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

18F FDG and 68Ga FAPI PET/MR Imaging of Carotid Artery Plaqu...

Carotid Artery Plaque

Actively Recruiting

1 location

320-detector Computed Tomography to Assess Myocardial Extrac...

Atrial Fibrillation

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here